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Abstract
Breast cancer (BrC) is a major health problem in women all around the world. A 
growing knowledge about these alterations and their associated molecular signaling 
pathways offers opportunities for therapeutic strategies; chemotherapy is one of the 
most utilized treatments; however, because of the adverse side effects and multidrug 
resistance that patients may present, there has been great advancement in search of 
new alternatives as the use of plant-derived natural compounds. This review describes 
information on the progress and development of cytotoxic compounds against BrC 
belonging to the families of flavonoids, terpenes, and alkaloids that through in vitro 
and in vivo studies have demonstrated to induce cellular death mainly through 
apoptosis, activating the intrinsic pathway. The in vitro IC50 and the in vivo EC50 
dose-response relationship can vary depending on various factors, including the 
choice of cell line and/or the model used. Also, the association of some of these com-
pounds with nanoparticles or paclitaxel with antibodies has clearly shown a potential 
improvement in its effect. The clinical studies that are being conducted with some of 
them show promising results; however, it is necessary to continue with the effort to 
develop new and more effective drugs against different types of BrC.
Keywords: breast cancer, cytotoxic agents, natural products, in vitro model,  
in vivo model, flavonoids, terpenoid, alkaloids, nanoparticles
1. Breast cancer (BrC)
Cancer is the uncontrolled and unregulated growth of cells that generally invade 
and destroy normal cells [1]. Breast cancer [BrC] is the deadliest malignancy in 
women worldwide and also an important public health problem being the second 
leading cause of cancer in women accounting for more than 626,679 deaths only in 
2018 [2]. In many cases this disease has become fatal because of its multifactorial ori-
gin and also because it has a great number of exogenous and endogenous factors that 
can stimulate different pathways [3]. In early BrC, gene expression profiles are deter-
mined for hormone receptor (HR)-positive disease and human epidermal growth 
factor type 2 receptor (HER2) status which define if a patient is likely to receive 
systemic therapy and are therefore used to guide their treatment [4]. Approximately 
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60–70% of primary BrC cases express positive estrogen receptors (ER+) or positive 
progesterone receptors (PR+) or both and are hormone responsive. However, about 
15–20% of BrC cases are in the category of triple-negative phenotype owing to their 
lack of ER, PR, and amplified HER2. Commonly, ER+ hormone-dependent BrCs 
have a better prognosis and are often responsive to antihormone therapy [4].
Because of these reasons, the survival rates for BrC have decreased significantly; 
however, there have been great advancements in new alternative therapies which 
not only are safer but are also more effective and inexpensive and have minimal 
side effects [5]. Therapeutic drugs derived from natural compounds have become 
of great interest since more than 75% of anticancer drugs were designed and 
developed from plant-derived natural ingredients which have been proven to have 
anticancer properties with novel mechanisms [6]. In the last 50 years, nearly 200 
new chemical compounds have been approved to fight cancer, of which around 50% 
are molecules of unmodified natural products and their semisynthetic or synthetic 
derivatives that are safe and profitable [7, 8]. Small organic molecules such as 
terpenes, flavonoids, alkaloids, lignans, saponins, vitamins, minerals, glycosides, 
oils, and other secondary metabolites play a significant role in either the inhibition 
of proliferation, induction of apoptosis, or other mechanisms that may be altered 
[9, 10]. The structural diversity of natural products and their wide application in 
therapeutics have always been recognized by pharmaceutical industries [1].
This chapter summarizes the small novel organic molecules obtained from 
plants and their derivatives, some of which are on the market and others are found 
in preclinical studies with encouraging results. We also describe some interesting 
biotechnological associations between some compounds and nanoparticles or other 
molecules as antibodies that show a novel potential in the treatment of BrC.
2.  In vitro models for studying plant-derived compounds  
in breast cancer
The evaluation of the therapeutic potential of novel plant-derived compounds 
or secondary metabolites, either pure compounds or the mixture of active constitu-
ents, can serve as chemotherapeutic agents in BrC. The biological models used for 
the development of new drugs include in vitro models using BrC cell lines and are 
divided into estrogen receptor positive (ER+, T47, MCF-7) and ER negative (ER-, 
MDA-MB-231, MDA-MB-453, SKBR3). MDA-MB-231 or triple-negative breast can-
cer cell (TNBC) line, estrogen negative (ER-) and progesterone negative (PR-), and 
HER- are known to be models for metastasis, which are more aggressive, containing 
a high potential to metastasize, and are unresponsive to antiestrogens [5, 8]. TNBC 
line is used to investigate the mechanism underlying migration and invasion. It is 
important to find cancer therapeutic compounds which possess multi-targeted and 
multifunctional potential with anti-metastasis activity [8, 11]. MCF-7 is the most 
used cell line with a great number of publications due to the presence of ER+ [9].
In vitro experiments have also been used in different studies, in order to char-
acterize and identify compounds derived from extracts, essential oils, and other 
extractions. Trypan blue dye, MTT, sulforhodamine B, and lactic dehydrogenase 
assays constitute some of the most utilized assays used to evaluate the cytotoxic 
effect of essential oils and/or pure compounds in different cell lines of BrC. In order 
to characterize morphological changes, biochemical and molecular levels of cell 
death, proteins that are modified (expression and activation), gene regulation, 
migration, invasion, and cell division, among other changes, experiments such as 
staining with hematoxylin and eosin, Western blot, TUNEL, annexin V, qRT-PCR, 
scratch assay, and cell cycle assays are performed [12].
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3. In vivo models for studying plant-derived compounds in breast cancer
Wide varieties of animal model systems are now available to investigate plant-
derived compounds in different stages, such as cancer initiation, promotion 
progression, invasion, and metastasis. These models are also used to comprehend 
therapeutic response, which represents an essential step between in vitro systems 
and clinical studies [8, 13]. The in vivo models are also used to investigate the capa-
bility of plant formulation to induce an anti-BrC effect where it is sought to opti-
mize dose, bioavailability, administration routes, and selective delivery and reduce 
toxic effects, among others [8, 14]. The two animal species that will be mentioned 
in this review are those involving mice and rats [14]; however, BrC mouse models 
are used in a variety of preclinical studies [13].
There are different types of in vivo models of BrC, such as cell line-derived 
xenografts (MDA-MB-231 line) that are implanted into immunocompromised 
animals (cell-derived xenografts, CDX). CDX models represent a relatively homog-
enous mass of transformed breast epithelial cells, and depending on where the 
cells are inoculated, they are classified as ectopic CDX (models advanced disease 
only, subcutaneous injection of human tumor cells), orthotopic CDX (in mammary 
gland/fat pad), metastatic CDX (following tail vein or intra-cardiac injection in 
specific sites, i.e., bone or lung), syngeneic (mouse tissue implanted to strain-
matched host) or metastasis with syngeneic model (usually fast-growing tumors 
and microenvironment derive from the same species, i.e., 4T1 cells), and genetically 
engineered mouse models (GEMMs) to address early events of tumorigenesis [13]. 
Nonetheless, researchers need to consider the limitations of each model and the 
mechanism of action of the compound previously investigated in in vitro models.
4. Cytotoxicity of plant-derived compounds
Plants produce bioactive secondary metabolites such as flavonoids [15], terpenoids 
[1], alkaloids [16], tannins, and others, which have profusely been studied for BrC  
(1, 8). Here, we describe some terpenoid compounds such as D-limonene, camptoth-
ecin (CPT), paclitaxel, and ursolic acid (UA) and some flavonoids such as cynaroside, 
isoflavones as Biochanin A (BA) or ginsenoside R2, naringenin, and other novel cyto-
toxic compounds from different natural sources as shown in Figure 1 and Table 1.
The anti-BrC activities of plant-derived compounds discussed in this chapter 
are taken from published articles that demonstrated an anti-BrC activity against 
specific cancer cell lines (see Table 2) and in vivo models (see Table 3) or clinical 
studies with their mechanism of action.
4.1 Terpenoids as cytotoxic compounds
Terpenoids are organic compounds derived from five-carbon units (isoprene) 
assembled and modified in different ways. The classification of terpenoids is based 
on the isoprene units which are commonly classified as monoterpenes (C10) and 
diterpenes (C20), i.e., paclitaxel, and triterpenes as ursolic acid [1]. Interestingly, 
essential oils are a rich and complex composition of monoterpenes with anti-BrC 
activity such as Decatropis bicolor essential oil (DBEO) [17].
4.1.1 D-limonene
D-limonene, (1-methyl-4-(1-methylethenyl-cyclohexene) a monocyclic mono-
terpene, with a molecular mass of 136.23 g/mol [18], is found in the peels of citrus 
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fruits [18–20]. The main mechanism described by D-limonene is the inhibition of 
the posttranslational isoprenylation of cell growth-regulatory proteins such as Ras, 
inducing cell death. It has also demonstrated to decrease the viability of cancer cells in 
a dose-dependent manner by inducing apoptotic cell death. It induced the activation 
of caspase-3 and caspase-9, PARP cleavage, and Bax protein and cytosolic release of 
cytochrome c from the mitochondria and through the attenuation of the expression 
of Bcl-2 protein, suggesting that D-limonene induces apoptosis via the mitochondrial 
pathway and through the suppression of the PI3K/AKT pathway [21, 22]. The interest 
in this compound as a potential cancer chemotherapeutic agent was stimulated by pro-
nounced chemopreventive and chemotherapeutic efficacy in spontaneous and carcin-
ogen-induced animal tumor models with little toxicity [19, 22]. In the in vivo models, 
it has been reported to exhibit various effects on several hallmarks of cancer (i.e., 
proliferation, apoptosis, inflammation) [23, 24]. 7,12-Dimethylbenz(a)anthracene 
(DMBA) and N-methyl-N-nitrosourea (MNU) induced mammary carcinogenesis in 
rats and induced regression of carcinomas [24–26]. Dietary feeding of D-limonene also 
inhibited the development of Ras oncogene in mammary carcinomas in rats [25].
Figure 1. 
Molecular targets of plant-derived compounds in BrC.
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4.1.2 Paclitaxel
Paclitaxel is a complex diterpene, with a molecular structure of C47H51NO14 
and a molecular mass of 853.91 g/mol [18]. This compound induces mitotic arrest 
and also apoptosis by activating extrinsic or intrinsic pathway. In MCF-7 cells it 
decreased levels of Bcl-2 protein and increased proapoptotic proteins such as Bax, 
cytochrome c, caspase-9, and caspase-3 [27, 28]. Likewise, it has also been reported 
Source Compound Study type Concentration Ref
Apples, herbs and spices 
including rosemary
Ursolic acid (UA) MCF-7, 
MDA-MB-231
221.39 μg/ml 239.47 μg/
ml
[33]
Apiaceae family, 
Cuminum cyminum
Cynaroside MCF-7 IC50:3.98 μg/ml [42]
Soybeans, soy foods, 
legumes
Biochanin (BA) MCF-7, 
MDA-MB-231
63.76 μm and 59.76 μm, 
respectively
[44]
Soybeans, soy foods, 
legumes
Ginsenoside (Rh2) MCF-7, 
MDA-MB-231
57.53 μm and 52.53 μm, 
respectively
[44]
Soybeans, soy foods, 
legumes
Ginsenoside + biochanin MDA-MB-231
MCF-7
27.68, 25.41 μm; 25.2 μm, 
and 22.75 μm
[44]
Tomatoes (Solanum 
lycopersicum), citrus 
fruits and grapes
Naringenin MDA-MB-231 40 μg/ml [43]
Soy products Genistein (GEN) MCF-7,
MDA-MB-231
/ERβ1
100 μm [48]
Tomatoes (Solanum 
lycopersicum), other red 
fruits
Lycopene (LYC) MDA-MB-231
MCF-7
≥1.25 μm to
5 μl in TNBC.
50 μm
[11, 
12]
LYC incorporated 
biopolymeric 
nanoparticles with 
whey protein isolate
Lycopene 
(LYC-WPI-NPs)
MCF-7 25–50 μm/ml [49]
A derivative from 
D-limonene
Perillyl alcohol a 
hydroxylated product of 
D-limonene
KPL-1, MCF-7, 
MKL-F,
MDA-MB-231
500 μm [26]
Taxus brevifolia Paclitaxel MCF-7
T47-D,
MBA-MB-231,
MDA-MB-435
100–500 nm [28]
Taxus brevifolia Paclitaxel-loaded 
nanospheres
MDA-MB-435, 
ZR.75.1
0.06–0.6 ng/ml [50]
Grapes, wine, nuts, 
berries
Resveratrol MCF-7 10–150 μm [51]
Camptotheca accuminata Camptothecin MDA-MB-231
MCF-7
100 nm
IC50:0.65 nm
[52, 
53]
Curcuma longa Curcumin MCF-7
MCF-7
MDA-MB-231
IC50: 29 μg/ml
IC50: 35 μm
IC50: 30 μm
[54, 
55]
Vinca alkaloids Vincristine MCF-7,
HeLa
IC50: 170 and 50 nmol/L [56]
Table 1. 
Cytotoxic effect of plant-derived compounds in in vitro models of BrC.
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that the induction of apoptosis was independent of caspases [29]. The combination 
of paclitaxel with a compound that inhibits the mitotic slippage such as phenylethyl 
isothiocyanate (PEITC) induced apoptosis in MDA-MB-231 cells which are drug 
resistance [30]. Also, additional activities of taxol have been described including 
the effect on cell signaling and gene expression and activation of mitogen-activated 
protein kinases (MAPKs), Raf-1, and protein tyrosine kinases [29]. Paclitaxel has 
been approved by the FDA to be used alone, or in combination with other antican-
cer treatments, to treat BrC and other cancers [31, 32].
4.1.3 Ursolic acid
Ursolic acid (3-β-hydroxy-urs-12-en-28-oic acid) is a pentacyclic triterpenoid 
natural product and a member of the cyclosqualenoid family, commonly named 
as UA with a molecular structure of C30H48C3 and a molecular mass of 456.7 g/mol 
[18]. UA is derived from diverse plants and fruits, such as rosemary (Rosmarinus 
officinalis), apple (Malus domestica), makino, cranberries (Vaccinium macrocarpon), 
pears (Pyrus pyrifolia), prunes (Prunus domestica), bearberries (Arctostaphylos 
alpina), loquat (Eriobotrya japonica), scotch heather (Calluna vulgaris), basil 
(Ocimum sanctum), and jamun (Eugenia jambolana) [9, 11]. UA posed different 
activity against BrC via several molecular mechanisms [7, 11, 33–35], and UA 
Compound Study type Dose and activity Ref
D-Limonene DMBA and NMU-
induced mammary 
carcinogenesis in rats
10% of limonene diet. Induced complete 
regression of primary rat mammary 
tumors and prevented the development of 
secondary tumors
[24]
Perillyl alcohol 
a hydroxylated 
product of 
D-limonene
Mammary rat tumor 
induced with KPL-1 
cells
75 mg/kg. Suppressed orthotopically 
transplanted KPL-1 tumor cell growth and 
regional lymph node metastasis in a nude 
mouse system
[26]
Paclitaxel-
encapsulated 
liposomes
DMBA mammary 
tumor
20 mg/kg. In combination with 500 mg/
kg of Eruca sativa extract reduced NF-κB, 
COX-2 and Bcl-2 gene expression
[97]
Paclitaxel-loaded 
nanospheres
Tumor xenograft 
model in mice
5–50 mg/kg. Showed an equivalent 
antitumor efficacy to the clinical 
formulation and provided a superior 
safety and improved tolerability to higher 
paclitaxel doses
[50]
Resveratrol DMBA induced 
mammary cancer 
in rats
estrogen-induced 
breast carcinoma in 
rats
100 μg/rat. Suppressed COX-2 and matrix 
metalloprotease-9 expression in the breast 
tumor.
50 mg. Inhibits breast carcinogenesis via 
induction of NRF2-mediated protective 
pathways
[67, 98]
Curcumin MCF-7 xenografts 
mouse breast cancer 
model
100 mg/kg in combination with mitomycin 
1–2 mg/kg. The combined treatment 
inhibited tumor growth, induced G1 
arrest, and decreased cyclin D1, cyclin E, 
cyclin A, CDK2, and CDK4
[99]
Camptothecin Mouse 4T1 breast 
tumor model
2 mg/kg in combination with 1.05 mg/kg 
of doxorubicin. Induced 70% of tumor 
volume reduction and caspase-3 induction
[100]
Table 2. 
Compounds evaluated in in vivo model of BrC.
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is relatively nontoxic to normal cells [11]. Administration of UA demonstrates 
inhibitory efficacy against cell proliferation rate and induces apoptosis via both 
the mitochondrial death pathway (cleavage of caspase-9, caspase-3, and PARP, Bax 
upregulation and Bcl-2 downregulation, release of cytochrome c to the cytosol, 
decreased mitochondrial membrane potential) and extrinsic death receptor-
dependent pathway (Fas receptor) in MDA-MB-231 cells [9, 11]. The treatment 
D-Limonene
PubChem CID:22311
Camptothecin
PubChem CID:24360
Paclitaxel
PubChem CID:36314
Ursolic acid
PubChem CID: 64945
Lycopene
PubChem CID: 446925
Cynaroside
PubChem CID: 5280637
Naringenin
PubChem CID: 932
Biochanin
PubChem CID: 5280373
Ginsenoside Rh2
PubChem CID: 119307
Genistein
PubChem CID: 5280961
Resveratrol
PubChem CID: 445154
Curcumin
PubChem CID:969516
Table 3. 
Structures of plant-derived compounds with potential effect in the BrC treatment.
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of BrC cells with UA induced changes in glycolytic pathway leading to cytotoxic 
autophagy, also at low doses (5–20 μm) caused a G0/G1 cell cycle arrest, increased 
p21 levels, oxidative stress, and DNA damage [36]. UA has been demonstrated to 
exhibit strong anti-BrC potential by inducing cell cycle arrest and inhibition of 
proliferation, angiogenesis, and metastasis in both in vitro and in vivo models [7, 11, 
33–35]. Finally, UA inhibited BrC growth by inducing cell death via the inhibition of 
inflammatory responses through the NF-κB, PI3K/AKT signaling pathways [9, 33]. 
Therefore, UA could be used as a potential anti-BrC strategy in clinical studies.
4.1.4 Lycopene alone
Lycopene (LYC) (trans-lycopene) is a terpene assembled from eight isoprene 
units and is a rich antioxidant compound, a major carotenoid present in tomatoes 
(Solanum lycopersicum), apricots, red oranges, pink grapefruit, watermelon, rose 
hips, guava, vegetables, and photosynthetic algae [37]. LYC has a molecular struc-
ture of C40H56 and a molecular mass of 536.888 g/mol [18]. LYC is a compound 
that has displayed antiproliferative, anti-migration, anti-invasive, anti-metastatic, 
and antioxidant characteristics in numerous in vitro and in vivo studies in BrC [9, 
37–39]. Also, LYC induces apoptosis and activates caspase-9 enzyme in human BrC 
cells [9]. Finally, LYC has inhibited the multiplication of cancer cells by arresting 
cell cycle at different phases (G1, S, and M phases) and by sustained activation 
of the ERK½ with suppression of cyclin D1 and upregulation of p21 [39]. Other 
mechanism of action of LYC is through the inhibition of IκBα phosphorylation and 
decrease in the expression of NF-κB [40].
4.1.5 Decatropis bicolor essential oil: a mixture of monoterpenes
Essential oils are a complex mixture of secondary metabolites such as monoter-
penes that are responsible for their biological activity that includes anti-BrC effect. 
However, some studies suggested a synergistic activity of the compounds [17]. For 
example, DBEO was studied on MDA-MB-231 cells.
It had a cytotoxic effect with an IC50 of 53.81 μg/ml. It induced DNA fragmenta-
tion and apoptosis via intrinsic pathways due to the activation of Bax, caspase-9, 
and caspases-3, suggesting a synergistic activity of compounds present in the essen-
tial oil, such as 1,5-cyclooctadiene, 3-(methyl-2)propenyl, β-terpineol, 1-(3-methyl-
cyclopent-2-enyl)-cyclohexene, D-limonene, pinene, and linalool [41].
4.2 Flavonoids as cytotoxic compounds
Flavonoids which are polyphenolic substances found in different plant-derived 
food are divided into flavones (cynaroside), flavonols, flavanones (naringenin), 
flavanols, isoflavones (genistein (GEN), biochanin A), anthocyanidins, and 
nonflavonoids [10]. Flavonoids have been reported to have an effect on BrC through 
numerous mechanisms such as antioxidant, anti-inflammatory, antiproliferative, 
cytotoxic, anti-angiogenic, and anti-metastatic effects in numerous in vitro and 
in vivo experiments in estrogen-dependent or estrogen-independent BrC [15, 37] 
(Tables 1–3).
4.2.1 Cynaroside
Cynaroside (luteolin-7-O-glucoside) is a glycosyloxyflavone or a glycoside form. 
It derives from luteolin. Cynaroside has a molecular structure of C21H20O11 and a 
molecular mass of 448.38 g/mol [18]. Cynaroside is a constituent of the leaves of 
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Capsicum annuum (red pepper) and seeds and fruits of Cuminum cyminum, an old 
famous medicinal and culinary plant from the Apiaceae family. Currently, Goodarzi 
and collaborators demonstrated that luteolin-7-O-glucoside plays a significant role in 
cytotoxic effect of C. cyminum against MCF-7 cell line (IC50 of 3.98 μg/ml) and can 
be introduced as a candidate for chemopreventive and chemotherapeutic drugs [42]. 
More in vitro or in vivo studies are necessary to elucidate its mechanism of action.
4.2.2 Naringenin
Naringenin (4',5,7-trihydroxyflavanone) is a flavanone and member of 
4'hydroxyflavanones; it has a molecular structure of C15H12O5 and a molecular 
mass of 272.256 g/mol [18]. This bioflavonoid is a constituent of tomatoes, citrus 
fruits, and grapes. Naringenin is a phytoestrogen which is also an important anti-
BrC, reported to be involved in decreasing the number of ER-α-positive cells by 
modulating p38 MAPK signaling pathway [9]. Recently, investigators reported that 
naringenin has antiproliferative effects by arresting the cell cycle at the G2 phase 
and caused an inhibitory effect on MDA-MB-231 cells via induction of apoptosis 
and inhibition of caspase-3 and caspase-9 activities [37, 43].
4.2.3 Biochanin and ginsenoside Rh2 as pure compounds or mixture
Biochanin or 4'-methylgenistein (B5,7-dihydroxy-4’-methoxyisoflavone) is an 
O-methylated isoflavone that is isolated from red clover Trifolium pratense and the 
root of Astragalus membranaceus, a traditional Chinese herbal medicine. BA has a 
molecular structure of C16H12O5 and a molecular mass of 284.267 g/mol [18, 44]. 
The phytoestrogen BA caused antiproliferative activity by stabilizing and activating 
p53 through the upregulated expression of phospho-p53, phospho-p38, and p-ASK1 
and downregulated expression of TRAF2 in MDA-MB-231 and MCF-7 cells [44] 
and apoptosis through upregulated expression of mRNA levels of ER-α, Bcl-2, and 
miR-375 in ER+ BrC cells, that is to say T47D and MCF-7 [37, 44, 45].
Also, BA stopped cell growth by blocking the activity of aromatase enzyme 
which is encoded by the gene CYP19 [5]. On the other hand, ginsenoside Rh2 
(protopanaxadiol-type) is the major type of saponin ginsenoside that is separated 
from Panax ginseng and other species. Rh2 has a molecular structure of C36H62O8 
and a molecular mass of 622.884 g/mol [18, 44]. Rh2 exhibits antitumor activity in 
ER+(MCF-7) and ER-(MDA-MB-231). However, Ren and collaborators determined 
that BA plus Rh2 synergistically enhanced the antiproliferative effect in both BrC 
cells, with decreased EC50 values of both the compounds and a mechanism through 
the stabilization and activation of p53, p38, and ASK1 proteins (Table 1) [44].
4.2.4 Genistein
Genistein (4',5,7-trihydroxyisoflavone) is an isoflavonoid derived from soy 
products [46]. It has a molecular structure of C15H10O5 and a molecular mass of 
270.24 g/mol [18]. This agent has an antineoplastic effect in BrC [47]. GEN inhibits 
the growth of MDA-MB-231 cells by altering the phosphorylation of proteins 
included in cell cycle regulation and DNA damage response predominantly, and 
GEN induced apoptosis via the upregulation of Bax and p21WAF1 proteins in 
MDA-MB-231 cells and downregulating the expression of caspase-3 [5, 47]. In a 
recent study, GEN increases cell cycle arrest in G2/M phase in MDA-MB-231/ERβ1 
cells, even though there is a high dose of GEN-arrested cells in G0/G1, just like in 
the MCF-7 cells. Thus, the combinatorial effect of GEN and overexpressed ERβ1 
resulted in an active blockade of cell cycle progression and a dramatic inhibition 
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of proliferation in vitro in MCF7 and MDA-MB-231 cells [48]. GEN could be a 
potential therapeutic agent for ERβ1-positive cancer, which merits further clinical 
research in the future.
4.2.5 Resveratrol
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a natural nonflavonoid polyphe-
nol with a molecular formula of C14H12O3 [18]. These compounds are isolated from 
more than 72 species of plants including peanuts, grapes, mulberries, bilberries, 
and blueberries [9].
Numerous in vitro studies have shown that resveratrol has multiple anticancer 
effects, which protect the cells against both tumor initiation and cancer progres-
sion pathway [9, 57]. The activity of this compound was described in hormone-
dependent or non-hormone-dependent BrC cells, in which it was found to induce 
apoptosis by intrinsic pathway through the upregulation of Bax, Bak, caspase-3, 
p53, and Akt pathway in different breast cancer cell lines and downregulated 
Bcl-2 and NF-kB and VEGF [51, 58–62]. Also, it can induce the extrinsic pathway 
through the expression of CD95 receptor [63]. A cell surface resveratrol receptor 
on the extracellular domain of heterodimeric αVβ3-integrin in MCF-7 human BrC 
cells induces extracellular-regulated kinases 1 and 2 (ERK1/2) and serine-15-p53-
dependent phosphorylation leading to a p53-dependent apoptosis [57]. In several 
in vivo models, resveratrol supplementation was shown to decrease the incidence 
of mammary tumor formation, tumor volume, metastasis, and induced apoptosis 
[64–66]. The effect of resveratrol demonstrated lower tumor growth, decreased 
angiogenesis, and increased apoptotic index in ERα− and ERβ+ [62]. Also, the 
following can suppress mammary carcinogenesis in rats induced by DMBA: dietary 
administration of resveratrol (10 ppm), downregulation of NF-kB, cyclooxygen-
ase-2 and matrix metalloprotease-9 expression in the breast tumor, and decreased 
tumor incidence [67, 68].
The effect of resveratrol in cancer patients has been investigated in a few clinical 
trials. The first clinical trial dealing with resveratrol and cancer was performed by 
Nguyen and collaborators in 2009, through the administration of 0.07 mg/day of 
resveratrol which resulted in the reduction of Wnt target gene expression, indicat-
ing that it may play a beneficial role in the prevention of cancer. These clinical trials 
have demonstrated resveratrol to be a promising therapeutic and chemopreventive 
agent [64, 69, 70].
4.2.6 Curcumin
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is 
an orange-yellow component of turmeric or curry powder; it is a polyphenol natu-
ral product isolated from the rhizome of Curcuma longa [9, 71]. Curcumin has anti-
proliferative and proapoptotic effects against a variety of cancer cells in vitro. The 
anticancer effects observed by activating intrinsic apoptotic pathway by interacting 
with reactive oxygen species can release cytochrome C; upregulate caspase-9, cas-
pase-3, Bax, and Bad; downregulate Bcl-2 antiapoptotic proteins; and induce DNA 
fragmentation in different BrC cell lines [72–75]. Also, it was found that curcumin 
inhibits the expression of Ki-67, proliferating cell nuclear antigen (PCNA), p53, 
and VEGF in BrC cells [54, 76]. Curcumin prevents carcinogen-induced cancers in 
rodents [77]. Banerjee et al. [79] reported that curcumin-induced G2/M arrest and 
apoptosis inhibited cell proliferation in MCF-7 cells, leading to an accumulation in 
the G1 phase, and suppressed the expression of zeste homolog 2 (EZH2) gene via 
MAPK pathway [78, 79].
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4.3 Alkaloids as cytotoxic compounds
Alkaloids are a highly diverse group of compounds containing an organic nitro-
gen atom and a ring structure. Additionally, in most alkaloids the nitrogen atom is 
located inside the heterocyclic ring structure, which gives them a great biological 
diversity [16]. The structural diversity of this family is due to the wide number of 
amino acids used as building blocks [80]. Indeed, the peptide ring that they contain 
has one or more of its hydrogen atoms replaced with various alkyl radicals, most 
of which contain oxygen [81, 82]. Consequently, alkaloids can interact with a wide 
spectrum of molecules. They have a wide distribution in the plant kingdom and are a 
chemically heterogeneous group of ~17,000 molecules which have displayed pro-
nounced biological and pharmacological activities. Furthermore, several alkaloids 
exhibit significant biological activities, with their unlimited supply of variable struc-
tures as well as their relatively low toxicity and well-documented stability; therefore, 
alkaloids are being used for their anticancer activity against various cancers [83].
4.3.1 Camptothecin
Camptothecin is a monoterpene indole alkaloid that consists of five rings [18], 
commonly named as CPT with a molecular structure of C20H16N2C4 and a molecular 
mass of 348.35 g/mol [18]. The antitumor activity of this compound is mainly due 
to its interaction with topoisomerase I (Top1), an enzyme involved in the regulation 
of DNA topology during replication, recombination, and transcription. It induces 
cell death by stabilizing a covalent complex between DNA topoisomerase I and the 
nicked DNA, leading to a DNA lesion [84–87].
CPT antitumoral activity has been reported in different cancer cell lines. Low 
doses of this compound lead to cell cycle arrest in the G2/M phase and inhibit DNA 
synthesis but at higher doses cause cell cycle arrest in S phase [52]. Also, the expres-
sion of some genes as c-Myc, Bax, BFL1, Bak, pRb2, c-Jun, and Jun-B was upregu-
lated, and Cdk4, cyclin B1, Wee1, CRAF1, and DP1 were downregulated. Among 
these derivatives, camptothecin-20(s)-O-(2-pyrazolyl-1)acetic ester exhibited 
antitumor activity which demonstrated cytotoxicity, DNA fragmentation, and 
apoptosis toward MCF-7 cell line [53]. Also, in different studies in vivo, where it 
was delivered using an intralipid formulation through intramuscular (IM) route, 
CPT showed nearly 100% growth inhibition and regression in the colon, lung, 
breast, stomach, and ovary and malignant melanoma xenografts [88, 89].
4.3.2 Vinca alkaloids: vinblastine, vincristine, and vinorelbine
There are some vinca alkaloids in clinical use such as vinblastine, vinorelbine, 
and vincristine. Many alkaloids have poisonous characteristics but also have physi-
ological effects that make them useful as medications. The oldest group of the plant 
alkaloids used to treat cancer is the vinca alkaloids. They have a dimeric chemical 
structure composed of two basic multi-ringed units, an indole nucleus (catharan-
thine) and a dihydroindole nucleus (vindoline), joined together with other complex 
systems. Structurally, vincristine and vinblastine are identical except for a single 
substitution on the vindoline nucleus, where vincristine and vinblastine possess 
formyl and methyl groups, respectively [90, 91] (Table 2). The main mechanisms of 
vinca alkaloid cytotoxicity is due to their interactions with tubulin and disruption of 
microtubule function, particularly of microtubules comprising the mitotic spindle 
apparatus, directly causing metaphase arrest. The disturbing effects occur at drug 
concentrations below those that decrease microtubule mass [91, 92]. Also, disorgani-
zation of the microtubule structure provokes the induction of tumor suppressor gene 
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p53 and activation/inactivation of several protein kinases involved in key signaling 
pathways, including p21, WAF1/CIP1, Ras/Raf, and PKC/PKA, the apoptosis inhibi-
tor Bcl2 and induction of Bax triggering the process of apoptosis in the cell [93]. These 
alkaloids demonstrated significant antitumor activity in patients with BrC. Also, 
xenograft mice models were used to evaluate low doses of vinblastine, which resulted 
in significant but transient xenograft regression, diminishing tumor vascularity, and 
direct inhibition of angiogenesis. Also, a combination therapy resulted in full and 
sustained regressions of large established tumors, without an ensuing increase in host 
toxicity or any signs of acquired drug resistance during treatment [94].
The risk of side effects and multidrug resistance limited the development of 
vinca alkaloids for clinical applications. To solve these problems, researchers have 
developed numerous strategies, such as using liposome-entrapped drugs, chemi-
cally modified drugs, and polymeric packaging drugs, to reduce the toxicity and 
enhance the therapeutic efficiency of vinca alkaloids. Many liposome products are 
still being tested in clinical trials. Another strategy for reducing chemotherapeutic 
toxicity involves using chemically modified drugs [95, 96].
5.  Biotechnological and clinical advances of plant-derived  
compounds in breast cancer
Nanotechnology has been found to potentially improve current methods for 
disease, diagnosis, disease-state imaging, and treatment in BrC.
Targeted nanoparticle drug delivery is intended to reduce the side effects of anti-
cancer drugs with both decreasing consumption and treatment expenses, which are 
the major hurdles in conventional cancer treatment. These small entities can be used 
in combination with a variety of plant-derived compounds in BrC with a variety of 
formulations being developed, making them a desirable choice of drug formulation [8].
5.1 Use of phytochemical compounds coupled to nanoparticles
5.1.1 Lycopene with nanoparticles
Recently, Jain and collaborators designed and synthesized LYC incorporated with 
biopolymeric nanoparticles with whey protein isolate nanoparticles (WPI NPs) 
with encouraging results in the compatibility of LYC-WPI-NPs over plain LYC as an 
optimum delivery system in vitro because encapsulation process did not affect its 
anticancer activity even in in vivo tumor model of DMBA where ~57% of LYC group 
of animals developed tumor compared with ~29% of LYC-WPI-NPs. The new for-
mulation (LYC-WPI-NPs) posed higher cytotoxicity and cellular uptake efficacy as 
compared to the plain LYC in MCF-7 cells. Antitumoral effect of LYC-WPI-NPs and 
survival data indicate that proposed formulation strategy is a novel approach for the 
synchronized delivery of bioactive compound, leading to increased bioavailability, 
therapeutic efficacy, and safety profiling because of improvement in animal survival 
(100%), in contrast to animals free of LYC (66.67%) and negative control group 
(16.67%). This will certainly open new avenues to explore cancer treatment [49].
5.1.2 Paclitaxel with nanoparticles
As a strongly hydrophobic drug, it requires suitable delivery vehicles to effec-
tively distribute into tumor tissues. For efficient distribution of this hydrophobic 
anticancer drug, paclitaxel is currently formulated and administered to patients 
via polyethoxylated castor oil (Cremophor EL, CrEL), but it is reported as causing 
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hypersensitivity reactions and neurotoxicity [101]. To date, paclitaxel albumin-
bound nanoparticles (Abraxane®) have been approved by the FDA for the treat-
ment of metastatic BrC and non-small cell lung cancer [8]. Nanoparticle-based 
delivery systems can take advantage of the enhanced permeability and retention 
(EPR) effect for passive tumor targeting; therefore, they can improve the therapeu-
tic index and decrease the side effects of paclitaxel. In addition, there are a number 
of novel paclitaxel nanoparticle formulations in clinical trials [50, 101–104]. 
Nanoparticle-assisted chemotherapeutic drug delivery has been used because it 
enhances therapeutic effectiveness. Studies on metastatic BrC demonstrate the 
inhibition of metastasis by co-delivering chemotherapeutic agent paclitaxel and 
twist shRNA via complex nanoparticles [105].
5.1.3 Camptothecin with nanoparticles
Research have concentrated on the development of potential delivery system to 
increase the aqueous solubility, stability, and bioavailability as well as controlled 
delivery of camptothecin at or around cancer tissues. For that purpose nanoencapsu-
lation of drugs in a biodegradable polymer has been reported to protect the drug in 
the core of the polymeric shell [106–108]. Camptothecin encapsulated in nanopar-
ticles demonstrated antitumor activity in in vitro and in vivo models; in MCF-7 cells 
the IC50 was lower (0.23 μm) than the pure compound (0.57 μm) [106, 109].
5.1.4 Curcumin with nanoparticles
As other compounds, in order to increase photostability and enhance its antican-
cer activity against BrC cells, scientists have formulated the transferrin-mediated 
solid lipid nanoparticle, which enhances the anticancer effect of curcumin in 
BrC cells in vitro [110]. A polymer-drug conjugate called polycurcumins also has 
advantages of high drug-loading efficiency, fixed drug-loading contents, stabilized 
curcumin in their backbones, and tailored water solubility. The polycurcumins are 
cytotoxic to cancer cells, but a polyacetal-based polycurcumin is highly cytotoxic 
to MCF-7 cells. The effect of these polymers induced cell cycle arrest and apoptosis 
partially through the caspase-3-dependent pathway. In vivo, this polymer showed 
antitumor activity in SKOV-3 intraperitoneal xenograft tumor model [111].
5.2 Novel therapies: antibody-phytopharmaceutical conjugates in breast cancer
In recent years, natural products and their derivatives have been among the major 
sources of drugs for the treatment of cancer as well as nanoparticles or antibodies. 
Furthermore, new treatments for different cases of BrC are necessary; this involves 
linking each cytotoxic drug concerned with a mAb by a linker group to produce a tri-
partite drug called an “antibody-drug conjugate” (ADC). A means of selective delivery 
of highly cytotoxic natural products as “prodrugs” to tumor cells has proven necessary 
in order to reduce off-target effects and increase therapeutic outcomes [8, 112].
5.2.1  Plant natural products as components of development ADCs: nab-paclitaxel 
or Abraxane®
The plant-derived compounds are secondary metabolites that have a different 
mechanism of action; although all of them are cytotoxic for BrC cells, new tools are 
being sought to increase their effectiveness, with less toxic effects. Also, incorporation 
of paclitaxel in liposomes can facilitate its delivery to cancer cells and eliminate the 
adverse reactions associated with the Cremophor EL vehicle. The lipid components of 
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the liposomal formulation were nontoxic, but the intracellular paclitaxel levels were 
higher when MCF-7 cells were treated with the liposomal paclitaxel formulation; 
also, liposomal paclitaxel was as effective as conventional paclitaxel in inducing G2/M 
arrest after 1 day of treatment with 10 mmol/L, increasing the percentage of cells in 
this population from about 20% in cycling cells to over 60% after 7 days [104].
Abraxane® or nanoparticle albumin-bound paclitaxel (nab-paclitaxel) suspen-
sion demonstrated greater efficacy with less toxicity than docetaxel in metastatic 
BrC. This treatment has been approved to reduce toxicity and increased overall 
survival rates, compared to the parent compound [8]. Nab-paclitaxel is a neoadju-
vant chemotherapy in HER2-negative BrC stages I, II, and III.
The recommended dose of Abraxane® is 260 mg/m2 administered intravenously 
for 30 minutes, every 3 weeks. The results suggest that Abraxane® is effective in 
patients with highly proliferative cancers (81).
6. Conclusion
In nature, plants contain secondary metabolites, which have been used by 
humans to treat different diseases, since they have a complex diversity of chemical 
structures that have been specifically related to have anti-BrC activity in several 
preclinical studies with more than one mechanism of action; as a result, they can 
provide greater degree of efficacy. Several natural compounds are highlighted 
in this chapter, and their mechanism of action, synergistic action, nano-formu-
lations, and future potentials are widely discussed, and due to the promising 
potential they represent, in fact, some of them are already used as treatment for 
BrC. However, it is necessary to have a greater diversity of drugs to be able to treat 
each one of the different tumors of BrC, since each BrC is different and many of 
these drugs may still induce several side effects and the development of mecha-
nisms of resistance to drugs must be avoided. Subsequent from this review, we can 
conclude that although there are many compounds that have been characterized 
mainly in in vitro models and only around 10–20% of these were also evaluated in 
in vivo models and less than 10% are being evaluated already in clinical phases, it is 
essential to conduct more research on these compounds to learn their mechanism 
of action. Also, in their cellular, biochemical, and molecular levels, clinical effects 
as well as their genetic toxicities should be investigated sufficiently. Compounds 
that meet the eligibility criteria in these tests should be taken into clinical trial 
phase, and they may be administered in combination with other compounds or 
materials that make their pharmacological effect more efficient, make their arrival 
to the target site more selective, and guarantee their stability, bioavailability, 
pharmacokinetics, etc. In conclusion, addressing the study of these compounds in 
clinical phase is a pressing need.
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